Prospective of Nanotechnology Application for the Treatment of HCV

Autor:	Jahangeer, Muhammad, Zawar Hussain, Azka Maryam, Areej Riasat, Ambreen, Alia, Shoukat Hussain, Mahmood, Zahed, Wasfa Batool, Mahvish Ashiq, Sumia Urainab
Rok vydání:	2023
Předmět:	FOS: Nanotechnology Hepatitis C Virus Biocompatibility Nanotechnology Nanoparticles Bio-Conjugation
DOI:	10.5281/zenodo.7585915
Popis:	Chronic Hepatitis C infection is a common worldwide disorder, caused by Hepatitis C Virus (HCV). Right around 180 million individuals are affected by Hepatitis C Virus infection globally and more than 50 million in South Asia. Ribavirin and interferon are used for many years for the treatment of HCV, direct acting agents, and combination therapy as well. The main problem with these therapies is that a lot of side effects are observed. A novel procedure is utilized for the treatment of HCV which is called nanotechnology. The major advantages of those technology are that there is no wastage of drugs and avoid the hydrolysis of drugs. Different kinds of the bearer are utilized as a part of the treatment of HCV like nanoparticles, bio-conjugation, micelle development and dendrites. Diverse sorts of Nano transporters are utilized that convey the medication stacked particles to target points and diminish symptoms. According to this description, the part of nanocomposite like a transporter for anti-hepatitis C virus vaccine, anti-hepatitis C virus deoxyribozymes, anti-HCV aptamers, anti-HCV phenolic compounds and their focused-on conveyance are talked about. Additionally, nanoparticles give a different strategy to antigen conveyance, which not just actuates distinctive components of the same framework yet, in addition, has great biocompatibility. {"references":["1.\tSchaefer EA, Chung RT. Anti− Hepatitis C Virus Drugs in Development. Gastroenterology. 2012 May 1;142(6):1340-50.","2.\tShepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet infectious diseases. 2005 Sep 1;5(9):558-67.","3.\tBlach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, Waked I, Alavian SM, Lee MH, Negro F, Abaalkhail F. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The lancet Gastroenterology & hepatology. 2017 Mar 1;2(3):161-76.","4.\tPetruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World journal of gastroenterology. 2016 Sep 9;22(34):7824.","5.\tMcEwan P, Ward T, Webster S, Kalsekar A, Brenner M, Yuan Y. Modeling the cost-effectiveness of the all oral, direct-acting antiviral regimen daclatasvir plus sofosbuvir in patients co-infected with hepatitis C virus (HCV) and HIV. Value in Health. 2015 Nov 1;18(7):A628..","6.\tFonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruíz-Pacheco JA, Cazares F, Vaughan G. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. Journal of clinical microbiology. 2012 Feb;50(2):281-7.","7.\tMukherjee P, Bhattacharya R, Bone N, Lee YK, Patra CR, Wang S, Lu L, Secreto C, Banerjee PC, Yaszemski MJ, Kay NE. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. Journal of nanobiotechnology. 2007 Dec;5(1):1-3","8.\tSingh S, Pandey VK, Tewari RP, Agarwal V. Nanoparticle based drug delivery system: advantages and applications. Indian J Sci Technol. 2011 Mar;4(3):177-80.","9.\tPetros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews Drug discovery. 2010 Aug;9(8):615-27.","10.\tPillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T‐cell responses. Journal of viral hepatitis. 2007 May;14(5):318-29.","11.\tKamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun 1;54(6):858-66.","12.\tLoustaud-Ratti V, Debette-Gratien M, Jacques J, Alain S, Marquet P, Sautereau D, Rousseau A, Carrier P. Ribavirin: Past, present and future. World journal of hepatology. 2016 Jan 18;8(2):123.","13.\tChampion JA, Mitragotri S. Role of target geometry in phagocytosis. Proceedings of the National Academy of Sciences. 2006 Mar 28;103(13):4930-4.","14.\tKumar A, Ma H, Zhang X, Huang K, Jin S, Liu J, Wei T, Cao W, Zou G, Liang XJ. Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials. 2012 Feb 1;33(4):1180-9.","15.\tLow PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Accounts of chemical research. 2008 Jan 15;41(1):120-9.","16.\tSaito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Advanced drug delivery reviews. 2003 Feb 10;55(2):199-215.","17.\tSinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics. 2006 Aug;5(8):1909-17.","18.\tGabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid–PEG conjugates. Advanced drug delivery reviews. 2004 Apr 29;56(8):1177-92.","19.\tMisra R, Sahoo SK. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. European Journal of Pharmaceutical Sciences. 2010 Jan 31;39(1-3):152-63.","20.\tÇağdaş M, Sezer AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. Application of nanotechnology in drug delivery. 2014 Jul 25;1:1-50.","21.\tYang S, Yuan W, Jin T. Formulating protein therapeutics into particulate forms. Expert Opinion on Drug Delivery. 2009 Oct 1;6(10):1123-33.","22.\tClark AJ, Davis ME. Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core. Proceedings of the National Academy of Sciences. 2015 Oct 6;112(40):12486-91.","23.\tParker WB. Metabolism and antiviral activity of ribavirin. Virus research. 2005 Feb 1;107(2):165-71.","24.\tJyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I. Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication. International Journal of Nanomedicine. 2015;10:903.","25.\tBobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Beer BE, Geijtenbeek TB, Chisari FV, Gallay PA. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proceedings of the National Academy of Sciences. 2008 Apr 8;105(14):5525-30.","26.\tLakshminarayanan A, Reddy BU, Raghav N, Ravi VK, Kumar A, Maiti PK, Sood AK, Jayaraman N, Das S. A galactose-functionalized dendritic siRNA-nanovector to potentiate hepatitis C inhibition in liver cells. Nanoscale. 2015;7(40):16921-31.","27.\tYang JA, Park K, Jung H, Kim H, Hong SW, Yoon SK, Hahn SK. Target specific hyaluronic acid–interferon alpha conjugate for the treatment of hepatitis C virus infection. Biomaterials. 2011 Nov 1;32(33):8722-9.","28.\tTorrecilla J, del Pozo-Rodríguez A, Apaolaza PS, Solinís MÁ, Rodríguez-Gascón A. Solid lipid nanoparticles as non-viral vector for the treatment of chronic hepatitis C by RNA interference. International journal of pharmaceutics. 2015 Feb 1;479(1):181-8.","29.\tHang X, Peng H, Song H, Qi Z, Miao X, Xu W. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro. Journal of virological methods. 2015 Sep 15;222:150-7.","30.\tRyoo SR, Jang H, Kim KS, Lee B, Kim KB, Kim YK, Yeo WS, Lee Y, Kim DE, Min DH. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials. 2012 Mar 1;33(9):2754-61.","31.\tRipoli M, Angelico R, Sacco P, Ceglie A, Mangia A. Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection. Journal of biomedical nanotechnology. 2016 Apr 1;12(4):770-80.","32.\tDore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology. 2015 Feb 1;148(2):355-66.","33.\tWagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010 Jun;51(6):1912-21.","34.\tMin DH, Kim DE. Suppression of hepatitis C viral genome replication with RNA-cleaving deoxyribozyme. InFrom nucleic acids sequences to molecular medicine 2012 (pp. 429-452). Springer, Berlin, Heidelberg.","35.\tMaeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced drug delivery reviews. 2013 Jan 1;65(1):71-9.","36.\tLuke JM, Simon GG, Söderholm J, Errett JS, August JT, Gale Jr M, Hodgson CP, Williams JA. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. Journal of virology. 2011 Feb 1;85(3):1370-83.","37.\tPan Q, Tilanus HW, Janssen HL, van der Laan LJ. Prospects of RNAi and microRNA-based therapies for hepatitis C. Expert opinion on biological therapy. 2009 Jun 1;9(6):713-24.","38.\tPrabhu R, Garry RF, Dash S. RETRACTED ARTICLE: Small interfering RNA targeted to stem-loop II of the 5'untranslated region effectively inhibits expression of six HCV genotypes. Virology Journal. 2006 Dec;3(1):1-1.","39.\tDykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chemical Society Reviews. 2012;41(6):2256-82.","40.\tKim M, Shin D, Kim SI, Park M. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus research. 2006 Dec 1;122(1-2):1-0.","41.\tKannan RM, Nance E, Kannan S, Tomalia DA. Emerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications. Journal of internal medicine. 2014 Dec;276(6):579-617.","42.\tWu J, Kamaly N, Shi J, Zhao L, Xiao Z, Hollett G, John R, Ray S, Xu X, Zhang X, Kantoff PW. Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. Angewandte Chemie International Edition. 2014 Aug 18;53(34):8975-9.","43.\tZender L, Hütker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gösling T, Flemming P, Malek NP, Trautwein C. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proceedings of the National Academy of Sciences. 2003 Jun 24;100(13):7797-802.","44.\tKamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical reviews. 2016 Feb 24;116(4):2602-63.","45.\tZekri AR, Bahnassy AA, El-Din HM, Salama HM. Consensus siRNA for inhibition of HCV genotype-4 replication. Virology Journal. 2009 Dec;6(1):1-9.","46.\tWong PT, Choi SK. Mechanisms of drug release in nanotherapeutic delivery systems. Chemical reviews. 2015 May 13;115(9):3388-432.","47.\tZhang S, Gao H, Bao G. Physical principles of nanoparticle cellular endocytosis. ACS nano. 2015 Sep 22;9(9):8655-71.","48.\tHubbell JA, Langer R. Translating materials design to the clinic. Nature materials. 2013 Nov;12(11):963-6.","49.\tElberry MH, Darwish NH, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virology Journal. 2017 Dec;14(1):1-0.","50.\tCanu IG, Schulte PA, Riediker M, Fatkhutdinova L, Bergamaschi E. Methodological, political and legal issues in the assessment of the effects of nanotechnology on human health. J Epidemiol Community Health. 2018 Feb 1;72(2):148-53.","51.\tIshihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. Journal of pharmaceutical sciences. 2014 Dec 1;103(12):4005-11.","52.\tOchekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part 2: nanostructures for drug delivery. Tropical Journal of Pharmaceutical Research. 2009;8(3)."]}
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::917c68fa0bf7df7792ff780560f6def5 Zobrazit plný text záznamu